

Figure S1. ARG2 impairs autophagy and enhances TP53, mTORC2-AKT-mTORC1-RPS6KB1 and impairs PRKAA signaling independently of its enzymatic activity in HAECs. The young HAECs were transduced with empty vector rAd/CMV-V5 as control (V5), rAd/CMV-Arg2 (Arg2) or rAd/CMV-Arg2-H160F (H160F, an inactive Arg2 mutant). 48 hours post transduction, cells were starved in serum-free medium for 16 hours. During the last 1 hour of incubation prior to the experiment, the cells were either untreated or treated with Baf A1 (20 nmol/L, 1 hour) as indicated. 64 hours post transduction, the cells were subjected to immunoblotting analysis for the parameters as indicated. TUBULIN served as loading control. The bar graph presents the quantification of the signals (n=3). *p<0.05, **p<0.01, ****p<0.001 vs. V5-control group within the corresponding experimental condition.




Figure S2. ARG1 is not detectable in young or senescent HUVEC. The young and senescent HUVECs were subjected to immunoblotting for ARG1 expression. P: positive control of human ARG1 expressed from plasmid pBudCE4.1-hARG1. TUBULIN served as loading control.




Figure S3. ARGINASE inhibitors do not restore impaired autophagy nor reduce augmented RPS6KB1 signaling in senescent HUVEC. The senescent HUVECs were either untreated (Con) or treated with ARGINASE inhibitors BEC (200 μ mol/L) or nor-NOHA (50 μ mol/L) overnight in serum-free medium and then subjected to immunoblotting for LC3-I/II, ATG12–ATG5 conjugate and SQSTM1, RPS6-S235/236 and RPS6. TUBULIN served as loading control. The quantification of the signals is shown in the graphs in the right panels.